Biocon Limited has informed the Exchange regarding a press release dated November 11, 2025, titled "Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%; PBT (before exceptional items) at Rs 183 Cr, Up 153%".
Press Release Nov 11 2025
Filed with NSE · · 13 pages · English
Release
In the deck
Earlier from Biocon
- Press Release Oct 23 2025
- Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®
- Press Release Oct 16 2025
- Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options
- Press Release Oct 01 2025
Later from Biocon
- Biocon Limited Press Release Dec 02 2025
- Biocon Limited Press Release Dec 06 2025
- Press Release Dec 11 2025
- Press Release Dec 13 2025
- Biocon Limited Press Release Dec 15 2025
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon